Mouding County

Bicycle Health Doctors Fly to Alabama for a Second Year to Ensure Opioid Treatment Continuity for Patients

Retrieved on: 
Tuesday, July 25, 2023
Telehealth, Mouding County, Face, Urine, Buprenorphine, Act, Opioid use disorder, Ground substance, Prescription, OUD, Social stigma, Bicycle, Addiction medicine, DEA, Patient, Transport, Safety, Pharmaceutical industry, Health insurance, Nursing

2022-302 , which prohibited clinicians from writing prescriptions for controlled substances and other medications via telemedicine without an in-person visit.

Key Points: 
  • 2022-302 , which prohibited clinicians from writing prescriptions for controlled substances and other medications via telemedicine without an in-person visit.
  • This decision left over 500 Bicycle Health patients who were utilizing medications for opioid use disorder (MOUD) – such as buprenorphine – scrambling to find in-person care options or otherwise face abandoning the treatment plan they had built via Bicycle Health.
  • This year, Bicycle Health returned once again to Alabama to renew access for 162 established patients who were still unable to find a local Alabama provider.
  • Bicycle Health’s team successfully completed in-person evaluations with 98.8% of these patients over the course of 3 days.

Cessation Therapeutics’ Anti-Fentanyl Monoclonal Antibody Treatment Shows Promise in Protecting Against Fentanyl-Induced Overdose

Retrieved on: 
Tuesday, February 28, 2023
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, McLean Hospital, Death, Development, National Institute on Drug Abuse, Respiratory system, Fentanyl, Research and development, Doctor of Philosophy, Anesthesia, Harvard University, Mouding County, Investigational New Drug, Opioid use disorder, Risk, Brain, Assistant, IND, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OUD, Harvard Medical School, NIH, Blood, Government, Bangladesh Technical Education Board, NIDA, Psychiatry, Food, Initiative, Pharmaceutical industry, Medical device, Research, U.S. government and smoking cessation

“Over 70,000 Americans died from fentanyl-related overdose in 2021 – that’s like having a 737 commercial airliner crash every single day.

Key Points: 
  • “Over 70,000 Americans died from fentanyl-related overdose in 2021 – that’s like having a 737 commercial airliner crash every single day.
  • The Cessation treatment does not enter or bind to receptors in the brain, thereby avoiding the risk of addiction.
  • If approved, Cessation’s antibody treatment would be the first marketed product designed for the prevention of fentanyl overdose.
  • “Fentanyl overdose is killing thousands of Americans every month, and there are currently no FDA-approved products specifically designed to prevent it.

NASADAD and AATOD Release New Information about Patients Being Treated in Opioid Treatment Programs (OTPs)

Retrieved on: 
Monday, December 5, 2022
Opioid, Substance Abuse and Mental Health Services Administration, Opioid use disorder, ORN, American Association of Clinical Endocrinologists, National Association, State Alcohol and Tobacco Company of Iceland, Partnership, Patient, Mouding County, Treatment, Naltrexone, SAMHSA, Buprenorphine, Consultant, Methadone, Directory, Pharmaceutical industry, Substance Abuse, OTP

DC and NEW YORK, Dec. 5, 2022 /PRNewswire-PRWeb/ -- In order to capture current patient census data for people being treated for opioid use disorder in OTPs, the American Association for the Treatment of Opioid Dependence (AATOD) in partnership with the National Association of State Alcohol and Drug Abuse Directors (NASADAD), developed a census survey of all patients enrolled in treatment as of January 1, 2021, in Substance Abuse and Mental Health Service Administration (SAMHSA) certified OTPs in the United States (U.S.). The project was supported by the SAMHSA-funded Opioid Response Network (ORN).

Key Points: 
  • Of the 512,224 patients in OTPs who reported using MOUDs, 476,763 reported using methadone, 33,473 reported buprenorphine, and the remaining 1,988 reported using naltrexone.
  • Through this census, AATOD and NASADAD have captured crucial and actionable data to better understand treatment demand and demand for specific medications in OTPs.
  • ORN provides no costs education, training and consultation to enhance efforts addressing the opioid and stimulant use disorder crisis.
  • ORN has representation across the country to help others in applying locally relevant, evidence-based practices across harm reduction, prevention, treatment and recovery.